Stem Cell Research

CASE REPORT Open Access

An unusual hematopoietic stem cell transplantation for donor acute lymphoblastic leukemia: a case report Di Zhou†, Ting Xie†, Suning Chen2, Yipeng Ling1, Yueyi Xu1, Bing Chen1, Jian Ouyang1 and Yonggong Yang1*

Abstract

Background: Donor acute lymphoblastic leukemia with recipient intact is a rare condition. We report a case of donor developing acute lymphoblastic leukemia 8 yrs after donating both bone marrow and peripheral blood hematopoietic stem cells.

Case presentation: This case report describes a 51-year old female diagnosed with acute lymphoblastic leukemia who donated both bone marrow and peripheral blood stem cells 8 yrs ago for her brother with severe aplastic anemia. Whole exome sequencing revealed leukemic genetic lesions (SF3B1 and BRAF mutation) only appeared in the donor sister, not the recipient, and an unusual type of hematopoietic stem cell transplantation with the recipient’s peripheral blood stem cells was done. The patient remained in remission for 3 months before disease relapsed. CD19 CAR-T therapy followed by HLA-identical unrelated hematopoietic stem cell transplantation was applied and the patient remains in remission for 7 months till now.

Conclusions: This donor leukemia report supports the hypothesis that genetic lesions happen randomly in leukemogenesis. SF3B1 combined with BRAF mutation might contribute to the development of acute lymphoblastic leukemia.

Keywords: Donor leukemia, Acute lymphoblastic leukemia, Hematopoietic stem cell transplantation, SF3B1, BRAF

Background Donor leukemia is a rare condition and only anecdotal reports described its development [1, 2]. There are two types of donor leukemia, literally the donor itself devel- oping leukemia or donor cells in the recipient develop- ing leukemia (Donor Cell Leukemia, DCL), which is more commonly reported. Two mechanisms have been proposed for DCL development: occult transfer of malig- nant cells from donors during hematopoietic stem cell transplantation (HSCT) or leukemic transformation of

healthy donor cells in recipients [3–6]. The latter one is unpredictable but it takes up the majority of DCL. Donor developing leukemia with recipient intact is even a rarer condition and only few reports described the de- velopment of acute myeloid leukemia (AML), not acute lymphoblastic leukemia (ALL), in peripheral blood stem cell (PBSC) donors [7, 8]. G-CSF administration was sus- pected for leukemogenesis but there have been no valid evidence to support the hypothesis. Meanwhile, there have been no reports describing the development of ALL in hematopoietic stem cell donors, not recipients. Here we reported a case with only the donor develop-

ing ALL 8 yrs after donating hematopoietic stem cells but not the recipient. Whole exome sequencing (WES) showed leukemic genetic lesions (SF3B1 and BRAF mu- tation) only appeared in the donor’s hematopoietic cells.

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

* Correspondence: [email protected] †Di Zhou and Ting Xie are co-first authors 1Department of Hematology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, 321 Zhongshan Road, Nanjing 210008, People’s Republic of China Full list of author information is available at the end of the article

Zhou et al. BMC Cancer (2020) 20:195 https://doi.org/10.1186/s12885-020-6681-2

A special type of HSCT using the recipient’s PBSCs was done. To our knowledge, this is the first case report of donor developing ALL and an unusual type of HSCT. We hope it could provide more evidence for donor leukemia formation and the potential role of SF3B1 and BRAF mutation in ALL.

Case presentation In May 2017, a 51-year old female presented to our hos- pital with over 1 week of fatigue. She has medical history of donating both bone marrow and PBSCs 8 yrs ago for her brother with severe aplastic anemia (SAA). G-CSF was used to mobilize hematopoietic stem cells for PBSC collection. Complete blood count (CBC) showed lym- phocytosis (Lymphocyte 10*10^9/L), moderate anemia (Hb 61 g/L) and thrombocytopenia (PLT 20*10^9/L). Peripheral blood smear demonstrated 30% of blast cells. Bone marrow biopsy showed lymphoblastic leukemia in- volving a markedly hypercellular marrow (Fig. 1). Flow cytometry showed the blasts expressed CD10, CD19, CD22, CD38, HLA-DR, but not CD13, CD33, CD117, or cytoplasmic MPO. Chromosomal analysis showed a nor- mal female karyotype. The diagnosis of B-ALL was made. VDP regimen (Vindesine, Daunorubicin, Prednis- one) was started after her diagnosis and bone marrow aspirate 14 days later revealed complete remission (CR). Then 2 cycles of VDLP regimen (Vindesine, Daunorubi- cin, Prednisone, Pegaspargase) and 2 cycles of MA (Mitoxantrone, Cytosine arabinoside) + Pegaspargase (PEG-Asp) regimen were administered. During this period, the patient remained in remission and cerebro- spinal fluid (CSF) remained clear after intermittent four time lumbar punctures. Minimal residue disease (MRD) monitoring by flow cytometry after each cycle did not detect blast cells with abnormal phenotype. Considering she has no other HLA-identical siblings or unrelated do- nors from China Bone Marrow Bank at that time and her brother, who was perfectly stable, a special type of

auto-HSCT using her brother’s PBSCs was performed in December 2017. Before the transplantation, whole ex- ome sequencing (WES) was done for both the donor and recipient to rule out occult genetic abnormalities in the stem cells. Results showed that only the patient, not her brother, has genetic mutations including SF3B1 and BRAF mutation associated with hematological malignan- cies in her hematopoietic cells, not oral mucosal cells (Table 1) [9–11]. Myeloablative conditioning regimen (Melphalan 140 mg/m2 d-3/d-2/d-1, Cytarabine 1 g/m2

d-3/d-2, Cyclophosphamide 60mg/Kg d-3/d-2) was used. A total of 2.34*10^6/kg CD34+ cells, 13.0*10^8/kg MNCs from peripheral blood were collected and trans- fused into the patient. Neutrophil engraftment occurred at day + 11 and platelet engraftment occurred at day + 14. VP regimen (Vindesine, Prednisone) and MTX + 6- MP regimen were used for maintenance therapy. Bone marrow aspirate and flow cytometry showed that the pa- tient remained in complete remission 3 months after transplantation. In May 2018, the patient’s CBC showed leukocytosis and bone marrow aspirate indicated disease relapsed with 53.33% blast cells. Flow cytometry showed the blasts expressed CD10, CD19, HLA-DR and partially expressed CD11b. Genetic testing using polymerase chain reaction (PCR) technique found that SF3B1 and BRAF exome mutation was negative. Re-induction chemotherapy with VDP regimen was administered, the patient achieved CR. However, after another 2 cycles of high-dose MTX+ PEG-Asp regimen, disease relapsed. In November 2018, CD19 CAR-T therapy followed by HLA-identical unrelated hematopoietic stem cell trans- plantation was applied and the patient remains in remis- sion for 7 months till now.

Discussion and conclusion Leukemogenesis is a complex process involving accumu- lation of genetic changes in self-renewing hematopoietic stem cells (HSCs) [12]. Two-hit model was proposed for

Fig. 1 Bone marrow biopsy of the patient showed a markedly hypercellular marrow implying ALL

Zhou et al. BMC Cancer (2020) 20:195 Page 2 of 5

the clonal evolution of leukemia [13]. Genome sequen- cing indicated that most mutations in the leukemia gen- ome were random events and the acquirement of one or two initiating mutations generated the founding clone for leukemogenesis [14]. In this case, a careful review of the medical history of both the brother and sister showed that there were no noteworthy differences in hazard substance exposure. During HSCT, the brother was exposed to more cytotoxic drugs, including CTX, MTX, CsA, while the sister was only exposed to short- time G-CSF before she developed ALL. WES revealed leukemic alterations including SF3B1 and BRAF muta- tion only happened in the donor sister. So we assumed that development of these mutations in her hematopoietic stem cells, not oral mucosal cells, were probably random events. SF3B1 gene is located at chromosome 2q33.1 and the

encoded protein is an essential component of the U2 small nuclear ribonucleoproteins complex (U2 snRNP), which functions by splicing pre-mRNAs. SF3B1 muta- tion often occurs in melanoma, chronic lymphocytic leukemia (CLL) or myelodysplastic syndrome (MDS)

[15]. Quesada et al. found that SF3B1 mutation could possibly alter its normal function by changing the phys- ical interactions with its binding partners [16]. Of note, U2 snRNP with mutated SF3B1 could affects the splicing of FOXP1 pre-mRNA resulting in the expression of truncated FOXP1 protein, which has been implicated in diffuse large B-cell lymphoma [17]. In this case, WES found SF3B1 R625H mutation in the patient’s blood cells but there have not been reports about the association between SF3B1 mutation and ALL. Considering the mu- tation could affect genes involved in malignant trans- formation of B cells like FOXP1, in might participate in the patient’s leukemogenesis. BRAF gene is located at chromosome 7q34 and it en-

codes a member of the Raf kinase family which regulates cell division, differentiation and secretion. More than 30 mutations of BRAF gene have been identified in human cancers and V600E was most frequently found [18]. It is a likely driver mutation in hairy cell leukemia and has been widely observed in melanoma, Langerhans cell his- tiocytosis, papillary thyroid carcinoma, colorectal cancer and non-small-cell lung cancer [19]. BRAF mutations

Table 1 Genetic mutations in the sister’s hematopoietic cells (Sample A), oral mucosal cells (Sample B) and the brother’s hematopoietic cells (Sample C) detected by WES

Gene Chrs Position Ref Allele

Alt Allele

Predicted Protein Variants

Genetic mutations shared by Sample A,B, C

ARHGEF10L 1 18,014,104 G A V794M, V972M, V719M, V1016M, V977M

YIF1B 19 38,798,111 T C Y234C, Y232C, Y249C, Y246C, Y218C

AMBRA1 11 46,529,825 C T R662H, R755H, R633H

ATRAID 2 27,438,205 T C C80R, C22R, C135R

CACNB3 12 49,212,737 G A G9R

IPO4 14 24,650,793 G C L991V

PLA2G15 16 68,293,133 C T P271L

ZNF574 19 42,582,813 T C S109P, S19P

NID2 14 52,505,486 T G N746H

ALG8 11 77,824,984 C T G242E

HOXB5 17 46,670,899 T C Y49C

TIE1 1 43,787,288 T G Y1083D, Y1038D

CACNA1F X 49,066,102 G C S1603C, S1614C, S1549C

FREM2 13 39,263,181 C G T567R

Genetic mutations shared by Sample A and C

ZGRF1 4 113,506,711 C T E1305K, E1363K

SLC43A2 17 1,495,007 C T

CHM X 85,134,073–85,134, 073

– A

Genetic mutations specific to Sample A SF3B1 2 198,267,483 C T R625H

BRAF 7 140,481,411 C T G466E

ZC3H7B 22 41,742,094 G C R516P

LAMC1 1 183,077,450 C T R255C

Sample A: the sister’s hematopoietic cells; Sample B: the sister’s oral mucosal cells; Sample C: the brother’s hematopoietic cells

Zhou et al. BMC Cancer (2020) 20:195 Page 3 of 5

could change the activation segment from inactive state into active state and enhance B-raf kinase activity, which augment cell proliferation. However, in ALL the fre- quency of BRAF mutation is very low and only V600E, G468A, L597Q mutations have been reported [20–22]. Helene Cav et al. reported that children with Noonan Syndrome, some of which harbor BRAF mutation, are at higher risk of developing ALL [23]. In this case, we found BRAF G466E in the patient, not her brother. It might form double hits with SF3B1 mutation, which could affect genes involved in pre-B cell differentiation, and ultimately leads to leukemogenesis in this patient. More basic research needs to be done to clarify the mechanism. ZC3H7B and LAMC1 gene mutations were also found

in the patient’s hematopoietic cells, but there have been no reports of them in hematological malignancies. Their roles in leukemogenesis still need to be uncovered. G-CSF is used in the majority of allogeneic

hematopoietic stem cell donations. Some studies showed its application was associated with increased risk of later development of MDS/AML [6, 8]. Meanwhile, some other studies failed to identify the correlation [24, 25]. It is a critical issue but it remains controversial. In our case, the donor developed ALL 8 yrs after hematopoietic stem cell mobilization using G-CSF. Her leukemogenesis and G-CSF usage were probably irrelevant since G-CSF is a regulator for granulopoiesis, not lymphopoiesis. The duration and dosage of G-CSF administration was longer and higher in the recipient brother, but till now no signs of MDS/AML have been detected in him. Therefore, high quality and more conclusive clinical data is needed to clarify G-CSF usage and leukemia formation espe- cially in healthy donors. The suspicion of delayed onset of DCL was also con-

sidered. According to previous reports of DCL, the aver- age latent period is within 4 yrs of HSCT [26, 27]. In our case, the recipient brother did not develop leukemia 8 yrs after transplantation. Additionally, WES showed no leukemia-associated gene mutations in him and it fur- ther ruled out the possibility of delayed leukemia onset. Auto-HSCT can be considered in MRD negative ALL

patients without appropriate HLA-identical donors. In this case, a special type of auto-HSCT was performed. Compared with stem cells collected from the patient herself, peripheral blood stem cells from her brother were leukemia cell free and it was supposed to lower the risk of disease relapse. However, the patient relapsed 3 months after transplantation. Since SF3B1 and BRAF mutation turned negative after disease relapsing, we hy- pothesized that leukemia sub-clones outgrew and caused disease relapse. To our knowledge, this is the first case report with

only donor developing ALL but not the recipient and

this is also the first report of an unusual type of auto- HSCT. We hope it could provide more evidence for the double-hit model in leukemogenesis and a potential al- ternative for donor leukemia treatment.

Abbreviations ALL: Acute Lymphoblastic Leukemia; Allo-HSCT: Allogenic Hematopoietic Stem Cell Transplantation; AML: Acute Myeloid Leukemia; ATG: Anti- Thymocyte Globulin; Auto-HSCT: Autologous Hematopoietic Stem Cell Transplantation; CsA: Cyclosporine A; CSF: Cerebrospinal Fluid; CTX: Cyclophosphamide; DCL: Donor Cell Leukemia; G-CSF: Granulocyte- Colony Stimulating Factor; GVHD: Graft Versus Host Disease; HSC: Hematopoietic Stem Cell; MNC: Mononuclear Cell; MTX: Methotrexate; PBSC: Peripheral Blood Stem Cell; PCR: polymerase chain reaction; SAA: Severe Aplastic Anemia; U2 snRNP: U2 small nuclear ribonucleoproteins complex; WES: Whole Exome Sequencing

Acknowledgements The authors would like to thank all the staff from the Department of Hematology, Drum Tower Hospital for their helpful suggestions when preparing this manuscript.

Authors’ contributions DZ wrote this manuscript. TX, YL and YX collected and analyzed patients’ clinical data. SC analyzed the WES result. JO, BC and YY were responsible for the treatment of patients. All Authors have read and approved the manuscript.

Funding No founding was received.

Availability of data and materials The clinical data used or analyzed in this case report are available from the corresponding author on reasonable request.

Ethics approval and consent to participate Patients provided written informed consent for genetic analysis based on the Declaration of Helsinki and were informed of the existence of other treatment options in accordance with the Ethics Committee of Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School.

Consent for publication Written informed consent was obtained from the patient for publication of this case report and accompanying images.

Competing interests The authors declare that they have no competing interests.

Author details 1Department of Hematology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, 321 Zhongshan Road, Nanjing 210008, People’s Republic of China. 2Jiangsu Institute of Hematology, First Affiliated Hospital of Soochow University, Suzhou, People’s Republic of China.

Received: 19 August 2019 Accepted: 26 February 2020

References 1. Niederwieser DW, Appelbaum FR, Gastl G, Gersdorf E, Meister B, Geissler D,

Tratkiewicz JA, Thaler J, Huber C. Inadvertent transmission of a donor's acute myeloid leukemia in bone marrow transplantation for chronic myelocytic leukemia. N Engl J Med. 1990;322(25):1794–6.

2. Ma H, Liu T. Development of donor cell leukemia following peripheral blood stem cell transplantation for severe aplastic anemia: a case report. Oncol Lett. 2016;11(6):3858–62.

3. Sala-Torra O, Hanna C, Loken MR, Flowers ME, Maris M, Ladne PA, Mason JR, Senitzer D, Rodriguez R, Forman SJ, et al. Evidence of donor-derived hematologic malignancies after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2006;12(5):511–7.

Zhou et al. BMC Cancer (2020) 20:195 Page 4 of 5

4. Loren AW, Porter DL, Stadtmauer EA, Tsai DE. Post-transplant lymphoproliferative disorder: a review. Bone Marrow Transplant. 2003;31(3): 145–55.

5. Blau O, Hofmann WK, Baldus CD, Thiel G, Serbent V, Schumann E, Thiel E, Blau IW. Chromosomal aberrations in bone marrow mesenchymal stroma cells from patients with myelodysplastic syndrome and acute myeloblastic leukemia. Exp Hematol. 2007;35(2):221–9.

6. Bennett CL, Evens AM, Andritsos LA, Balasubramanian L, Mai M, Fisher MJ, Kuzel TM, Angelotta C, McKoy JM, Vose JM, et al. Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the research on adverse drug events and reports (RADAR) project. Br J Haematol. 2006;135(5):642–50.

7. Glasser L, Meloni-Ehrig A, Greaves W, Demel KC, Butera J. Synchronous development of acute myeloid leukemia in recipient and donor after allogeneic bone marrow transplantation: report of a case with comments on donor evaluation. Transfusion. 2009;49(3):555–62.

8. Tigue CC, McKoy JM, Evens AM, Trifilio SM, Tallman MS, Bennett CL. Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the research on adverse drug events and reports project. Bone Marrow Transplant. 2007;40(3):185–92.

9. Hahn CN, Scott HS. Spliceosome mutations in hematopoietic malignancies. Nat Genet. 2011;44(1):9–10.

10. Tiacci E, Park JH, De Carolis L, Chung SS, Broccoli A, Scott S, Zaja F, Devlin S, Pulsoni A, Chung YR, et al. Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia. N Engl J Med. 2015;373(18):1733–47.

11. Xu Y, Wertheim G, Morrissette JJ, Bagg A. BRAF kinase domain mutations in de novo acute myeloid leukemia with monocytic differentiation. Leuk Lymphoma. 2017;58(3):743–5.

12. Korn C, Mendez-Ferrer S. Myeloid malignancies and the microenvironment. Blood. 2017;129(7):811–22.

13. Schneider F, Bohlander SK, Schneider S, Papadaki C, Kakadyia P, Dufour A, Vempati S, Unterhalt M, Feuring-Buske M, Buske C, et al. AML1-ETO meets JAK2: clinical evidence for the two hit model of leukemogenesis from a myeloproliferative syndrome progressing to acute myeloid leukemia. Leukemia. 2007;21(10):2199–201.

14. Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC, Wartman LD, Lamprecht TL, Liu F, Xia J, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012;150(2):264–78.

15. Wan Y, Wu CJ. SF3B1 mutations in chronic lymphocytic leukemia. Blood. 2013;121(23):4627–34.

16. Quesada V, Conde L, Villamor N, Ordonez GR, Jares P, Bassaganyas L, Ramsay AJ, Bea S, Pinyol M, Martinez-Trillos A, et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet. 2011;44(1):47–52.

17. Brown PJ, Ashe SL, Leich E, Burek C, Barrans S, Fenton JA, Jack AS, Pulford K, Rosenwald A, Banham AH. Potentially oncogenic B-cell activation-induced smaller isoforms of FOXP1 are highly expressed in the activated B cell-like subtype of DLBCL. Blood. 2008;111(5):2816–24.

18. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–54.

19. Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP, Pucciarini A, Bigerna B, Pacini R, Wells VA, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011;364(24):2305–15.

20. Lee JW, Soung YH, Park WS, Kim SY, Nam SW, Min WS, Lee JY, Yoo NJ, Lee SH. BRAF mutations in acute leukemias. Leukemia. 2004;18(1):170–2.

21. Hou P, Liu D, Xing M. The T1790A BRAF mutation (L597Q) in childhood acute lymphoblastic leukemia is a functional oncogene. Leukemia. 2007; 21(10):2216–8.

22. Alonso CM, Such E, Gomez-Segui I, Cervera J, Martinez-Cuadron D, Luna I, Ibanez M, Lopez-Pavia M, Vera B, Navarro I, et al. BRAF V600E mutation in adult acute lymphoblastic leukemia. Leuk Lymphoma. 2013;54(5):1105–6.

23. Cave H, Caye A, Strullu M, Aladjidi N, Vignal C, Ferster A, Mechinaud F, Domenech C, Pierri F, Contet A, et al. Acute lymphoblastic leukemia in the context of RASopathies. Eur J Med Genet. 2016;59(3):173–8.

24. Holig K, Kramer M, Kroschinsky F, Bornhauser M, Mengling T, Schmidt AH, Rutt C, Ehninger G. Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single- center experience in 3928 donors. Blood. 2009;114(18):3757–63.

25. Cavallaro AM, Lilleby K, Majolino I, Storb R, Appelbaum FR, Rowley SD, Bensinger WI. Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant. 2000;25(1):85–9.

26. Sala Torra O, Loeb KR. Donor cell-derived leukemia and myelodysplastic neoplasm: unique forms of leukemia. Am J Clin Pathol. 2011;135(4):501–4.

27. Hertenstein B, Hambach L, Bacigalupo A, Schmitz N, McCann S, Slavin S, Gratwohl A, Ferrant A, Elmaagacli A, Schwertfeger R, et al. Development of leukemia in donor cells after allogeneic stem cell transplantation--a survey of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2005;90(7):969–75.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Zhou et al. BMC Cancer (2020) 20:195 Page 5 of 5

© 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance

with the terms of the License.